Longwood Founders Fund

About The Fund

Longwood Founders Fund is an investment firm with a focus on creating and investing in science-based companies that craft novel solutions for significant medical problems. They are engaged in a range of industries, encompassing Software, IT & Technology, Media (TMT), Biotechnology, Medical Devices & Hospital Services, Investment Management, Life Science, and Oncology. With a mission to innovate, collaborate, and accelerate, Longwood adopts a hands-on approach, often partnering with world-class scientific co-founders to identify groundbreaking discoveries. They actively take on leadership roles such as Co-Founding CEO, CBO, or President to build companies and are considered value-add investors by supporting their portfolios to help advance therapies from the laboratory to patients. Longwood Fund has a strong track record with $170 billion in sustained market/exit value of companies co-founded by Longwood partners, over 20 therapies and products brought to market, and 35+ assets in clinical research seeking approval. They have co-founded 25 companies, leading to the creation of thousands of jobs in the Boston area. They also host semi-annual industry meetings with leaders across government, pharma, biotech, and academia, fostering dialogue for collaboration and innovation. Influential figures from the industry, such as Stefan Oelrich (CEO, Bayer Pharmaceuticals) and Bob Langer (Co-Founder, Moderna & Momenta), have endorsed Longwood's impact and contribution to the sector. Notable testimonies underline their trusted partnerships and role in launching successful ventures. Furthermore, Longwood's involvement extends to organizing major industry conferences that offer testimonials and insights from a first-class network of Boston's biotech ecosystem. Longwood's investment size ranges from a minimum of $14,100,000 to a maximum of $62,000,000, reflecting their commitment to significant, growth-oriented contributions to their chosen fields.